Tyme Technologies Stock Price - TYME

Best deals to access real time data!
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
DDE w/Realtime (Monthly)
Monthly Subscription
for only
Big Cap Pro
Monthly Subscription
for only
VAT not included
After Hours
Last Trade
Last $ 1.22 ▲ 0.01 (0.83%)
Company Name Stock Ticker Symbol Market Type
Tyme Technologies Inc New TYME NASDAQ Common Stock
  Price Change Change Percent Stock Price High Price Low Price Open Price Close Price Last Traded
  0.16 15.24% 1.21 1.22 1.08 1.08 1.05 23:59:44
Bid Price Ask Price Spread Spread % News
1.02 1.21 0.19 15.7% - 1
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
1,453 319,773 $ 1.14 $ 363,559 279,036 0.92 - 4.6417
Last Trade Time Type Quantity Stock Price Currency
16:40:05 1 $ 1.20 USD

Tyme Technologies Financials

Market Cap Shares in Issue Profit/Loss Earnings Per Share (EPS) PE Ratio Float
$ 135.46M 111.95M $ -18.97M -0.33 - 59.14M
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% -1.00 47.20%

more financials information »

Tyme Technologies News

Loading Messages....

Latest TYME Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical TYME Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week1.121.220.991.04367,5550.098.04%
1 Month1.521.530.991.20256,471-0.31-20.39%
3 Months1.151.890.991.40392,4490.065.22%
6 Months1.461.890.921.30633,699-0.25-17.12%
1 Year2.154.64170.922.14691,084-0.94-43.72%
3 Years4.49479.500.922.51425,671-3.28-73.08%
5 Years4.49479.500.922.51425,671-3.28-73.08%

Tyme Technologies Description

Tyme Technologies Inc is the U.S based clinical-stage biotechnology company. The company is focused on the development and commercialization of targeted cancer therapeutics with a broad range of oncology indications for humans. SM 88, its proprietary drug candidate compound, is a novel compound that has the potential to alter defenses to oxidative stress and increase free radical availability to the cancer cell. The company is currently conducting a Phase II trial in prostate cancer.

Your Recent History
Tyme Techn..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.